Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, Immunome, Inc. (IMNM) has a Wall Street consensus price target of $35.29, based on estimates from 9 covering analysts. With the stock currently trading at $21.86, this represents a potential upside of +61.4%. The company has a market capitalization of $2.00B.
Analyst price targets range from a low of $26.00 to a high of $40.00, representing a 40% spread in expectations. The median target of $36.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, IMNM trades at a trailing P/E of -4.4x. Analysts expect EPS to grow +0.3% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how IMNM stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for IMNM is $35.29, representing 61.4% upside from the current price of $21.86. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
IMNM has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $35.29 implies 61.4% upside from current levels.
IMNM's current price is $21.86 with a consensus target of $35.29 (61.4% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $40 for IMNM, while the most conservative target is $26. The consensus of $35.29 represents the median expectation. These targets typically reflect 12-month expectations.
IMNM is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month IMNM stock forecast based on 9 Wall Street analysts shows a consensus price target of $35.29, with estimates ranging from $26 (bear case) to $40 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on IMNM, with a "Buy" consensus rating and $35.29 price target (61.4% upside). 9 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
IMNM analyst price targets range from $26 to $40, a 40% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $35.29 consensus represents the middle ground.